A human vascularized microtumor model of patient-derived colorectal cancer recapitulates clinical disease

[1]  C. Dang,et al.  Targeting cancer metabolism in the era of precision oncology , 2021, Nature reviews. Drug discovery.

[2]  Yan Liu,et al.  A Direct and Sensitive Method for Determination of 5-Fluorouracil in Colorectal Cancer Cells: Evaluating the Effect of Stromal Cell on Drug Resistance of Cancer Cells , 2021, Journal of analytical methods in chemistry.

[3]  J. Lowengrub,et al.  An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy , 2021, Lab on a chip.

[4]  S. Sleijfer,et al.  Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features , 2021, Nature Communications.

[5]  O. W. Lindwasser,et al.  ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper , 2020, Nature Reviews Clinical Oncology.

[6]  Dustin E. Schones,et al.  Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth , 2020, Nature Communications.

[7]  F. Supek,et al.  Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns , 2020, Science Advances.

[8]  E. Cuppen,et al.  Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. , 2020, Cell reports.

[9]  E. Schuuring,et al.  Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy , 2020, Cancer and Metastasis Reviews.

[10]  E. Schuuring,et al.  Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy , 2020, Cancer and Metastasis Reviews.

[11]  Wenyuan Zhao,et al.  Vasculogenic mimicry in carcinogenesis and clinical applications , 2020, Journal of Hematology & Oncology.

[12]  S. Hanessian,et al.  Synthetic Sphingolipids with 1,2-Pyridazine Appendages Improve Antiproliferative Activity in Human Cancer Cell Lines. , 2020, ACS medicinal chemistry letters.

[13]  P. Galle,et al.  A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma , 2019, Clinical and translational gastroenterology.

[14]  Stephanie J Hachey,et al.  Applications of tumor chip technology. , 2018, Lab on a chip.

[15]  Honggang Zhou,et al.  Hsp90β promotes aggressive vasculogenic mimicry via epithelial–mesenchymal transition in hepatocellular carcinoma , 2018, Oncogene.

[16]  Lucie A. Low,et al.  ‘You-on-a-chip’ for precision medicine , 2018 .

[17]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[18]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[19]  L. Sequist,et al.  Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care , 2017, Cell reports.

[20]  Hellmut G. Augustin,et al.  Preclinical mouse solid tumour models: status quo, challenges and perspectives , 2017, Nature Reviews Cancer.

[21]  Steven C George,et al.  A vascularized and perfused organ-on-a-chip platform for large-scale drug screening applications. , 2017, Lab on a chip.

[22]  A. Wardley,et al.  Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis , 2016, Journal of Mammary Gland Biology and Neoplasia.

[23]  Stephanie J Hachey,et al.  3D microtumors in vitro supported by perfused vascular networks , 2016, Scientific Reports.

[24]  Guanglong Jiang,et al.  Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer , 2016, BMC Genomics.

[25]  L. Augenlicht,et al.  NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer-Initiating Cells. , 2016, Cancer research.

[26]  K. Śmietana,et al.  Trends in clinical success rates , 2016, Nature Reviews Drug Discovery.

[27]  S. Shah,et al.  Using Somatic Mutations to Guide Treatment Decisions: Context Matters. , 2015, JAMA Oncology.

[28]  N. Nishimura,et al.  Chemokine-Targeted Mouse Models of Human Primary and Metastatic Colorectal Cancer , 2015, Nature Biotechnology.

[29]  Enrico Gratton,et al.  Fluorescence lifetime imaging of endogenous biomarker of oxidative stress , 2015, Scientific Reports.

[30]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[31]  A. J. Bain,et al.  Separating NADH and NADPH fluorescence in live cells and tissues using FLIM , 2014, Nature Communications.

[32]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[33]  Enrico Gratton,et al.  Metabolic trajectory of cellular differentiation in small intestine by Phasor Fluorescence Lifetime Microscopy of NADH , 2012, Scientific Reports.

[34]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[35]  P. Pauwels,et al.  Prognostic Role of Vasculogenic Mimicry in Colorectal Cancer , 2009, Diseases of the colon and rectum.

[36]  E. Gratton,et al.  The phasor approach to fluorescence lifetime imaging analysis. , 2008, Biophysical journal.

[37]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.